Moderna 的股票暴跌，因为它预计由于疫苗需求下降，2025 年的收入将大幅下降。 Moderna's stock plunges as it projects a significant drop in 2025 revenue due to lower vaccine demand.

摩德纳公司的股价在预计2025年收入大幅下降后大幅下跌,从2024年的31亿美元降至15亿至25亿美元之间. Moderna's stock fell sharply after the company projected a significant drop in 2025 revenue, from $3.1 billion in 2024 to between $1.5 billion and $2.5 billion. 这一下降是由于对COVID-19疫苗Spikevax的需求量减少,以及其RSV疫苗的效绩不佳。 This decline is due to reduced demand for its COVID-19 vaccine, Spikevax, and underperformance of its RSV vaccine. 现代计划2025年将费用削减10亿美元,2026年再削减5亿美元,以弥补收入短缺。 Moderna plans to cut costs by $1 billion in 2025 and an additional $500 million in 2026 to offset the revenue shortfall. 在早期交易中股票下降了19%。 Shares dropped 19% in early trading.